ImmuPharma plc (LON:IMM – Get Free Report)’s stock price fell 10.5% on Tuesday . The company traded as low as GBX 2.60 ($0.03) and last traded at GBX 2.82 ($0.03). 2,858,942 shares traded hands during trading, a decline of 86% from the average session volume of 20,779,262 shares. The stock had previously closed at GBX 3.15 ($0.04).
ImmuPharma Price Performance
The firm has a market capitalization of £12.49 million, a PE ratio of -300.00 and a beta of 1.53. The company’s fifty day simple moving average is GBX 1.67 and its 200-day simple moving average is GBX 1.71.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Oracle Announces Game-Changing News for the AI Industry
- Why is the Ex-Dividend Date Significant to Investors?
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
